From a baseline HbA1 of 8.9%, the once-weekly insulin icodec achieved a superior reduction in estimated HbA1 of -1.68%-points compared with -1.31%-points for once-daily basal insulins.

Adults with type 2 diabetes lowered their HbA1c from 8.18% at baseline to 7% at 26 weeks with insulin icodec plus a CGM. Time in range improved by more than 20 percentage points during the study.

Eli Lilly’s efsitora has undergone phase 3 clinical trials, whereas Novo Nordisk’s once-weekly insulin icodec is currently under regulatory review. If either is approved by the FDA ...

Novo Nordisk is also pairing the long-acting insulin with its once-weekly GLP-1 agonist semaglutide in the COMBINE trials programme, which is due to complete in 2024, is also working on a glucose ...

Further information Dear stakeholders, As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of TSID 11940 Basal insulin ...

Correction: Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes. The Mifepristone Litigation: Untangling the Implications of ...

The document noted that “the rate of hypoglycemic episodes was significantly higher in the insulin icodec arm compared to the insulin degludec arm.” Time in Range (TIR) (70 to 180 mg/dL ...